ANAVEX LIFE SCIENCES CORP.AVXLEarnings & Financial Report
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical firm focused on developing novel small molecule therapeutics for neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease, Rett syndrome and Parkinson’s disease. It operates mainly across North America and European markets, targeting patients with high unmet medical needs.
Revenue
$1.4M
Gross Profit
N/A
Operating Profit
$-13.6M
Net Profit
$-12.1M
Gross Margin
N/A
Operating Margin
-975.0%
Net Margin
-868.8%
YoY Growth
-30.6%
EPS
$-0.14
ANAVEX LIFE SCIENCES CORP. Q1 FY2025 Financial Summary
ANAVEX LIFE SCIENCES CORP. reported revenue of $1.4M (down 30.6% YoY) for Q1 FY2025, with a net profit of $-12.1M (down 40.5% YoY) (-868.8% margin).
Key Financial Metrics
| Total Revenue | $1.4M |
|---|---|
| Net Profit | $-12.1M |
| Gross Margin | N/A |
| Operating Margin | -975.0% |
| Report Period | Q1 FY2025 |
ANAVEX LIFE SCIENCES CORP. Annual Revenue by Year
ANAVEX LIFE SCIENCES CORP. annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.7M).
| Year | Annual Revenue |
|---|---|
| 2025 | $4.7M |
| 2024 | $7.3M |
| 2023 | $6.5M |
ANAVEX LIFE SCIENCES CORP. Quarterly Revenue & Net Profit History
ANAVEX LIFE SCIENCES CORP. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $1.1M | -22.6% | $-5.7M | -526.5% |
| Q4 FY2025 | $999.0K | -43.2% | $-9.8M | -983.7% |
| Q3 FY2025 | $1.1M | -40.1% | $-13.2M | -1231.9% |
| Q2 FY2025 | $1.2M | -31.1% | $-11.2M | -925.3% |
| Q1 FY2025 | $1.4M | -30.6% | $-12.1M | -868.8% |
| Q4 FY2024 | $1.8M | -10.1% | $-11.6M | -660.2% |
| Q3 FY2024 | $1.8M | -1.8% | $-12.2M | -680.1% |
| Q2 FY2024 | $1.8M | +19.9% | $-10.5M | -600.6% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $1.8M | $1.8M | $1.4M | $1.2M | $1.1M | $999000 | $1.1M |
| YoY Growth | 19.9% | -1.8% | -10.1% | -30.6% | -31.1% | -40.1% | -43.2% | -22.6% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $144.5M | $141.5M | $135.6M | $124.0M | $117.1M | $102.4M | $103.8M | $133.0M |
| Liabilities | $9.6M | $11.8M | $15.3M | $13.1M | $17.4M | $11.5M | $8.9M | $6.4M |
| Equity | $135.0M | $129.8M | $120.3M | $110.9M | $99.8M | $91.0M | $94.9M | $126.6M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-11.7M | $-5.2M | $-6.7M | $-12.1M | $-5.9M | $-12.5M | $-8.6M | $-7.2M |